Binghe Xu

6PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Energy generation, conversion and storage (excl. chemical and electrical)Predictive and prognostic markersGene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 24, 2025
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.

Xiaoyan Qian, Xi Chen, Min Xiao

|Dec 19, 2025
Multicellular force coordination constructs microchannel networks for barrier-free metastasis across extracellular matrix.

Huan Gao, Bo Cheng, Guorui Jin

|Jun 19, 2025
The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study.

Bo Lan, Dan Lv, Changyuan Guo

|Mar 17, 2025
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.

Oleg Gluz, Binghe Xu, Rita Nanda

|Nov 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world study.

Yujing Tan, Zexi Peng, Hanfang Jiang

|Sep 04, 2024
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study.

Qingyuan Zhang, Pin Zhang, Min Yan

Pageof 1

Frequent Collaborators

3 joint publications

Fei Ma

2 joint publications

Bo Lan

1 joint publications

Yujing Tan

1 joint publications

Hope S Rugo